Incidence of carcinoma according to the type of neuropathy in our series and in several other published series
| Type of neuropathy (authors) | Number of cases | Incidence of carcinoma (%) | Follow up (mean value in our study) | Commentaries | |
|---|---|---|---|---|---|
| General population of neuropathies | |||||
| Prineaset al 35 | 278 | 5.4 | >18 months | ||
| Our study | 422 | 6.2 | ND | ||
| Guillain-Barré syndrome | |||||
| Halls et al 26 | 29 | 6.9 | >400 days | ||
| Italian study group37 | 297 | 0.7 | 24 months | % of death due to carcinoma within 250 days | |
| Our study4-150 | 59 | 1.7 | <2 y | ||
| CIDP | |||||
| Barhon et al 38 | 60 | 5.0 | NS | These studies include patients with MGUS of unknown reactivity | |
| Gorsonet al 39 | 67 | 0 | Mean 3 y | ||
| Our study4-150 | 38 | 10.5 | 5.7 y (0.5-16) | ||
| Vasculitis/mononeuritis multiplex | |||||
| Vincentet al 40 | 50 | 14 | NS | Patients selected from nerve biopsies | |
| Vincent et al 41 | 50 | 10 | NS | ||
| Haratiet al 42 | 33 | 9 | Mean 18.5 months | ||
| Our study4-150 | 20 | 10 | 2.3 y (0.5-10) | ||
| Axonal polyneuropathy of otherwise undetermined cause | |||||
| Fagius et al 43 | 91 | 1.0 | Mean 3.7 y | ||
| McLeodet al 44 | 47 | 10.6 | Median 3 y | ||
| Notermans et al 45 | 75 | 5.3 | 4.7 y | Prospective study | |
| Camerlingo et al 46 | 51 | 29.4 | Mean 51.4 months | Prospective study of patients with pure sensory neuropathy | |
| Our study4-150 | 67 | 10.3 | 3.7 y (0.3-11) | 4.5% within 2 years after onset | |
ND=not done; NS=not stated; MGUS=monoclonal gammopathy of unknown significance.
↵4-150 Patients with a short latency are taken into account only.